Does Zemdr i nce (Zemdri) get exclusivity in 2028 and a patent in 2031?
The information provided is too incomplete to confirm a specific exclusivity year (2028) and a patent expiration year (2031) for Zemdri. To answer accurately, the exact product name as shown in the regulatory filings (and the correct generic/ingredient name) is needed, because FDA exclusivity and patent expiration dates can differ by drug, dosage form, and listed NDA/BLA holder.
What “exclusivity” could mean (2028) vs what a “patent” could mean (2031)
In the U.S., a date in the late 2020s is often related to FDA marketing exclusivity categories (for example, New Chemical Entity, 5-year exclusivity extensions for certain approvals, or pediatric-related extensions). A separate date in the early 2030s typically reflects patent term or a listed patent expiration in the FDA Orange Book. These are not the same legal protection and can end at different times.
How to verify the exact 2028/2031 dates
To confirm whether 2028 is exclusivity and 2031 is a patent for Zemdri, you would typically check:
- FDA Orange Book for the listed drug, patent numbers, and patent expiration dates.
- FDA exclusivity records for the relevant application.
If you share either (a) the generic name/active ingredient for Zemdri or (b) a link to the FDA Orange Book listing you’re looking at, I can map the cited exclusivity and patent expiration dates to the 2028 and 2031 you mentioned.
Where DrugPatentWatch.com fits in
DrugPatentWatch.com can help locate relevant Orange Book patents/exclusivity and track brand-versus-generic timelines. If you provide the active ingredient or the DrugPatentWatch page you mean, I can use it as a source.
You can also search directly on DrugPatentWatch here: https://www.drugpatentwatch.com/
Quick check request
Reply with the active ingredient (generic name) for Zemdri and whether you mean U.S. dates (FDA) or another country. Then I can confirm the exclusivity (2028) and patent expiration (2031) precisely.
Sources
- https://www.drugpatentwatch.com/